🇺🇸 Systemic Chemotherapy in United States
13 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 13
Most-reported reactions
- Brain Oedema — 2 reports (15.38%)
- Hydrocephalus — 2 reports (15.38%)
- Intracranial Pressure Increased — 2 reports (15.38%)
- Anaemia — 1 report (7.69%)
- Brain Abscess — 1 report (7.69%)
- Breast Cancer Metastatic — 1 report (7.69%)
- Cerebrospinal Fluid Leakage — 1 report (7.69%)
- Hyponatraemia — 1 report (7.69%)
- Malignant Neoplasm Progression — 1 report (7.69%)
- Pain — 1 report (7.69%)
Other Oncology approved in United States
Frequently asked questions
Is Systemic Chemotherapy approved in United States?
Systemic Chemotherapy does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Systemic Chemotherapy in United States?
Second Affiliated Hospital, School of Medicine, Zhejiang University is the originator. The local marketing authorisation holder may differ — check the official source linked above.